Myocyte production of nitric oxide in response to AChR-reactive antibodies in two inbred rat strains may influence disease outcome in experimental myasthenia gravis

Clinical Immunology

Volumn 106, Issue 2, 2003, Pages 116-126

  Garcia, Yvonne R ^a   Pothitakis, Jennifer C ^a   Krolick, Keith A ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Acetylcholine receptor antibody; Autoimmune disease; iNOS; L NIL; Muscle; Myasthenia gravis; Nitric oxide; Nitric oxide synthase

Indexed keywords

CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR ANTIBODY; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISEASE RESISTANCE; DISEASE SIMULATION; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INDUCTION; ENZYME INHIBITION; FEMALE; HOST SUSCEPTIBILITY; IMMUNOMODULATION; IMMUNOREGULATION; INBRED STRAIN; MUSCLE CELL; MYASTHENIA GRAVIS; NONHUMAN; PRIORITY JOURNAL; RAT; SKELETAL MUSCLE; SPECIES COMPARISON; STRAIN DIFFERENCE; UPREGULATION;

EID: 0037303350     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6616(02)00023-2     Document Type: Article

References (38)

1. Lindstrom J., Shelton D., Fujii Y. Myasthenia gravis. Adv. Immunol. 42:1988;233-284.
2. Drachman D.B. Myasthenia gravis. N. Engl. J. Med. 330:1994;1797-1810.
3. Zoda T., Yeh T.M., Krolick K.A. Clonotypic analysis of anti-acetylcholine receptor antibodies from EAMG-sensitive Lewis rats and EAMG-resistant Wistar Furth rats. J. Immunol. 146:1991;663-670.
4. Krolick K.A., Thompson P.A., Zoda T.E., Mohan S., Yeh T.-M. Experimental myasthenia gravis role of immunological fine-specificity . Hohlfeld R. Immunology of Neuromuscular Diseases (Immunology & Medicine Series). Vol. 24:1994;209-233 Kluwer Academic, Dordrecht.
5. Lindstrom J., Seybold M.E., Lennon V.A., Whittingham S., Duane D.D. Antibody to acetylcholine receptor in myasthenia gravis prevalence, clinical correlates, and diagnostic value . Neurology. 26:1976;1054-1059.
6. Tindall R.S.A. Humoral immunity in myasthenia gravis clinical correlations of anti-receptor antibody avidity and titer . Ann. N.Y. Acad. Sci. 377:1981;316-329.
7. Drachman D.B., Adams R.N., Josifek L.F., Self S.G. Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis. N. Engl. J. Med. 307:1982;769-775.
8. Hohlfeld R., Sterz R., Kalies I., Wekerle H., Peper K. Experimental myasthenia lack of correlation between the autoantibody titer and the reduction of acetylcholine-controlled ionic channels measured at functioning endplates . Muscle Nerve. 6:1983;160-163.
9. Clancy R.M., Amin A.R., Abramson S.B. The role of nitric oxide in inflammation and immunity. Arthritis Rheum. 41:1998;1141-1151.
10. Tzartos S., Hochschwender S., Vasquez P., Lindstrom J. Passive transfer of experimental autoimmune myasthenia gravis by monoclonal antibodies to the main immunogenic region of the acetylcholine receptor. J. Neuroimmunol. 15:1987;185-194.
11. Thompson P.A., Krolick K.A. Acetylcholine receptor-reactive antibodies in experimental autoimmune myasthenia gravis differing in disease-causing potential subsetting by preparative isoelectric focusing . Clin. Immunol. Immunopathol. 62:1992;199-209.
12. Krolick K.A., Yeh T.-M., Edlund S.A. Lewis rats given antibodies against denatured acetylcholine receptor become resistant to induction of experimental autoimmune myasthenia gravis. Cell. Immunol. 172:1996;10-20. doi:10.1006/cimm.1996.0209.
13. Olsberg C.A., Maxwell L.C., Mikiten T.M., Krolick K.A. Analysis of contractile properties of muscles from rats immunized with purified acetylcholine receptor. J. Neuroimmunol. 14:1987;253-266.
14. Stegall T., Krolick K.A. A monoclonal Lewis rat myocyte line that responds to interferon-gamma responsiveness with the potential to influence subsequent interactions with the immune system . Clin. Immunol. 94:2000;125-132. doi: 10.1006/clim.1999.4821.
15. Garcia Y.R., May J.J., Green A.M., Krolick K.A. Acetylcholine receptor-reactive antibody induces nitric oxide production by a rat skeletal muscle cell line influence of cytokine environment . J. Neuroimmunol. 120:2001;103-111.
16. Kosuga K., Yui Y., Hattori R., Sase K., Eizawa H., Aoyama T., Inoue R., Sasayama S. Cloning of an inducible nitric oxide synthase from rat. Endothelium. 2:1994;217-221.
17. Murwani R., Hodgkinson S., Armati P. Tumor necrosis factor-α and interleukin-6 mRNA expression in neonatal Lewis rat Schwann cells and a neonatal rat Schwann cell line following interferon-γ stimulation. J. Neuroimmunol. 71:1996;65-71.
18. Hevel J.M., Marletta M.A. Nitric-oxide synthase assays. Methods Enzymol. 233:1994;250-258.
19. Gold D.P., Schroder K., Powell H.C., Kelly C.J. Nitric oxide and the immunomodulation of experimental allergic encephalomyelitis. Eur. J. Immunol. 27:1997;2863-2869.
20. Thompson P.A., Barohn R.A., Krolick K.A. Repetitive nerve stimulation vs. twitch tension in rats with EAMG. Muscle Nerve. 15:1991;94-100.
21. Stegall T., Krolick K.A. Myocytes respond in vivo to an antibody reactive with the acetylcholine receptor by up-regulating interleukin-15 an interferon-gamma activator with the potential to influence the severity and course of experimental myasthenia gravis . J. Neuroimmunol. 119:2001;377-386.
22. Krolick K.A., Zoda T.E., Thompson P.A. Examination of characteristics that may distinguish disease-causing from benign AChR-reactive antibodies in experimental autoimmune myasthenia gravis. Adv. Neuroimmunol. 4:1994;475-493.
23. S. Reyes-Reyna, T. Stegall, and K.A. Krolick, Muscle responds to an antibody reactive with the acetylcholine receptor by up-regulating MCP-1: a chemokine with the potential to influence the severity and course of experimental myasthenia gravis, J. Immunol. 169 (2002) 1579-1586.
24. Shi F.D., Flodstrom M., Kim S.H., Pakala S., Cleary M., Ljunggren H.G., Sarvetnick N. Control of the autoimmune response by type 2 nitric acid synthase. J. Immunol. 167:2001;3000-3006.
25. Gu D., Wogensen L., Calcutt N.A., Xia C., Zhu S., Merlie J.P., Fox H.S., Lindstrom J., Powell H.C., Sarvetnick N. Myasthenia gravis-like syndrome induced by expression of interferon gamma in the neuromuscular junction. J. Exp. Med. 181:1995;547-557.
26. Balasa B., Deng C., Lee J., Bradley L.M., Dalton D.K., Christadoss P., Sarvetnick N. Interferon gamma (IFN-γ) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice. J. Exp. Med. 186:1997;385-391.
27. Moiola L., Galbiati F., Nartino G., Amadio S., Brambilla E., Comi G., Vincent A., Grimaldi L., Adorini L. IL-12 is involved in the induction of experimental autoimmune myasthenia gravis, an antibody-mediated disease. Eur. J. Immunol. 28:1998;2487-2497.
28. Zhang G.X., Xiao B.G., Bai X.F., van der Meide P.H., Orn A., Link H. Mice with IFN-γ receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis. J. Immunol. 162:1999;3775-3787.
29. Shi F.D., Zhang G.X., Bai X.F., Van der Meide P.H., Link H. Cellular mRNA expression of interferon-gamma (IFN-gamma), IL-4 and IL-10 relates to resistance to experimental autoimmune myasthenia gravis (EAMG) in young Lewis rats. Clin. Exp. Immunol. 108:1997;523-528.
30. Wang H.B., Shi F.D., Li H., van der Meide P.H., Ljunggren H.G. Role for interferon-gamma in rat strains with different susceptibility to experimental autoimmune myasthenia gravis. Clin. Immunol. 95:2000;156-162. doi:10.1006/clim.2000.4850.
31. Reyes-Reyna S.M., Krolick K.A. Chemokine production by rat myocytes exposed to interferon-gamma. Clin. Immunol. 94:2000;105-113. doi: 10.1006/clim.1999.4828.
32. Shi F.D., Bai X.F., Li H.L., Link H. Macrophage apoptosis in muscle tissue in experimental autoimmune myasthenia gravis. Muscle Nerve. 21:1998;1071-1074.
33. Cowden W.B., Cullen F.A., Staykova M.A., Willenborg D.O. Nitric oxide is a potential down-regulating molecule in autoimmune disease inhibition of nitric oxide production renders PVG rats highly susceptible to EAE . J. Neuroimmunol. 88:1988;1-8.
34. Xiao B.G., Huang Y.M., Xu L.Y., Ishikawa M., Link H. Mechanisms of recovery from experimental allergic encephalomyelitis induced with myelin basic protein peptide 68-86 in Lewis rats a role for dendritic cells in inducing apoptosis of CD4+ T cells . J. Neuroimmunol. 97:1999;25-36.
35. Willenborg D.O., Fordham S.A., Staykova M.A., Ramshaw I.A., Cowden W.B. IFN-gamma is critical to the control of murine autoimmune encephalomyelitis and regulates both in the periphery and in the target tissue a possible role for nitric oxide . J. Immunol. 163:1999;278-286.
36. Xu L., Huang Y., Yang J., van der Meide P.H., Levi M., Wahren B., Link H., Xiao B. Dendritic cell-derived nitric oxide is involved in IL-4-induced suppression of experimental allergic encephalomyelitis (EAE) in Lewis rats. Clin. Exp. Immunol. 118:1999;115-121.
37. Tarrant T.K., Silver P.B., Wahlsten J.L., Rizzo L.V., Chan C.C., Wiggert B., Caspi R.R. Interleukin-12 protects from a T helper type 1-mediated autoimmune disease, experimental autoimmune uveitis, through a mechanism involving interferon gamma, nitric oxide, and apoptosis. J. Exp. Med. 189:1999;219-230.
38. Huang F.P., Niedbala W., Wei X.Q., Xu D., Feng G.J., Robinson J.H., Lam C., Liew F.Y. Nitric oxide regulates Th1 cell development through the inhibition of IL-12 synthesis by macrophages. Eur. J. Immunol. 28:1998;4062-4070.